GLP-1 Responses Are Heritable and Blunted in Acquired Obesity With High Liver Fat and Insulin Resistance
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
OBJECTIVE Impaired incretin response represents an early and uniform defect in type 2 diabetes, but the contributions of genes and the environment are poorly characterized. RESEARCH DESIGN AND METHODS We studied 35 monozygotic (MZ) and 75 dizygotic (DZ) twin pairs (discordant and concordant for obesity) to determine the heritability of glucagon-like peptide 1 (GLP-1) responses to an oral glucose tolerance test (OGTT) and the influence of acquired obesity to GLP-1, glucose-dependent insulinotropic peptide (GIP), and peptide YY (PYY) during OGTT or meal test. RESULTS The heritability of GLP-1 area under the curve was 67% (95% CI 45-80). Cotwins from weight-concordant MZ and DZ pairs and weight-discordant MZ pairs but concordant for liver fat content demonstrated similar glucose, insulin, and incretin profiles after the OGTT and meal tests. In contrast, higher insulin responses and blunted 60-min GLP-1 responses during the OGTT were observed in the heavier as compared with leaner MZ cotwins discordant for BMI, liver fat, and insulin sensitivity. Blunted GLP-1 response to OGTT was observed in heavier as compared with leaner DZ cotwins discordant for obesity and insulin sensitivity. CONCLUSIONS Whereas the GLP-1 response to the OGTT is heritable, an acquired unhealthy pattern of obesity characterized by liver fat accumulation and insulin resistance is closely related to impaired GLP-1 response in young adults.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132‐134).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [132]
In the citing paper
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132‐134).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [132]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 2×
“It must be noted that the DZ weight-discordant twin pairs did not undergo liver fat measurement but as a group they clearly represent the unhealthy obesity pattern based on significantly higher HOMA-IR and lower Matsuda indices.”
MethodIntroduction to Quantitative Genetics.
Edwards, A. W. F., & Falconer, D. S. (1982) · Biometrics · doi:10.2307/2529912 · Cited by 21,447
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 1×
“HOMA-IR (14) and Matsuda index (15) were calculated using glucose and insulin measurements from the OGTT measurements.”
MethodMethodology for Genetic Studies of Twins and Families
Neale, M. C., & Cardon, L. R. (1992) · doi:10.1007/978-94-015-8018-2 · Cited by 4,005
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
Self-citationByrd, W. P. (1961) · Agronomy Journal · doi:10.2134/agronj1961.00021962005300010026x · Cited by 1,572
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 3×
“A severely reduced incretin response is a uniform finding in type 2 diabetes, in which the β-cell insulin secretion due to incretins may be reduced to < 20% from that of healthy subjects (2).”
BackgroundResultTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919 · cited 1×
“The plasma concentrations of GLP-1 were measured (17) against standards of synthetic GLP-1 7-36amide using antiserum code #89390, which is specific for the amidated C-terminus of GLP-1 and therefore does not react with GLP-1containing peptides from the pancreas.”
MethodSelf-citationVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884 · cited 1×
“The data in subjects with diabetes on GLP-1 and GIP plasma levels are conflicting with studies reporting especially reduced, unaltered and increased GIP concentrations after OGTT (2, 30-33).”
ResultSelf-citationDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · cited 1×
“The data in subjects with diabetes on GLP-1 and GIP plasma levels are conflicting with studies reporting especially reduced, unaltered and increased GIP concentrations after OGTT (2, 30-33).”
ResultSelf-citationGenetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge
GIANT consortium, Saxena, R., the MAGIC investigators, Hivert, M.-F., Langenberg, C., Tanaka, T., Pankow, J. S., Vollenweider, P., Lyssenko, V., Bouatia-Naji, N., et al. (2010) · Nature Genetics · doi:10.1038/ng.521 · Cited by 626 · cited 1×
“Although several polymorphisms in the GIP receptor have been associated with both obesity and glycemia (3, 4), genetic loci predisposing to type 2 diabetes identified so far do not directly involve GLP-1 or GIP genes (5, 6).”
BackgroundMuscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · cited 1×
“The data in subjects with diabetes on GLP-1 and GIP plasma levels are conflicting with studies reporting especially reduced, unaltered and increased GIP concentrations after OGTT (2, 30-33).”
ResultSelf-citationThe continuing value of twin studies in the omics era
van Dongen, J., Slagboom, P. E., Draisma, H. H. M., Martin, N. G., & Boomsma, D. I. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3243 · Cited by 373 · cited 1×
“Phenotypically discordant MZ twins are of special interest as the two extremes of the phenotype do not differ in their genomic sequence but all of the variability in the phenotype is accounted for by variations in the environmental factors or geneenvironment interaction (9).”
BackgroundVollmer, K., Holst, J. J., Baller, B., Ellrichmann, M., Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2008) · Diabetes · doi:10.2337/db07-1124 · Cited by 356 · cited 1×
“Other limitations include lack of measurement of glucagon, which has been linked to impaired incretin response, and not performing laborious clamp studies, which would have directly measured insulin sensitivity and the b-cell incretin responses (37).”
BackgroundSelf-citationRask, E., Olsson, T., Söderberg, S., Johnson, O., Seckl, J., Holst, J. J., & Ahrén, B. (2001) · Diabetes Care · doi:10.2337/diacare.24.9.1640 · Cited by 229 · cited 1×
“Most of the previous data also support our view that impaired incretin response develops concomitantly with the features of insulin resistance rather than represents a primary genetic trait that drives the progress to type 2 diabetes (1, 26, 27).”
Self-citationKnop, F. K., Aaboe, K., Vilsbøll, T., Vølund, A., Holst, J. J., Krarup, T., & Madsbad, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01549.x · Cited by 195 · cited 1×
“Because incretin defect in type 2 diabetes appears early and apparently uniformly, the question under study has long been if altered secretion of incretins represents a primary genetic defect (21).”
BackgroundSelf-citationTCF7L2 Variant rs7903146 Affects the Risk of Type 2 Diabetes by Modulating Incretin Action
Villareal, D. T., Robertson, H., Bell, G. I., Patterson, B. W., Tran, H., Wice, B., & Polonsky, K. S. (2010) · Diabetes · doi:10.2337/db09-1169 · Cited by 162 · cited 1×
“Carriers of the T allele of TCLF7 variant rs7903146 demonstrate 30% loss of the incretin effect suggesting impaired β-cell capacity to respond to incretin stimulus (28).”
BackgroundVaag, A. A., Holst, J. J., Vølund, A., & Beck-Nielsen, H. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1350425 · Cited by 154 · cited 1×
“Most of the previous data also support our view that impaired incretin response develops concomitantly with the features of insulin resistance rather than represents a primary genetic trait that drives the progress to type 2 diabetes (1, 26, 27).”
Self-citationKrarup, T., Madsbad, S., Moody, A. J., Regeur, L., Faber, O. K., Holst, J. J., & Sestoft, L. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-56-6-1306 · Cited by 151 · cited 1×
“For the GIP radioimmunoassay (16) we used the C-terminally directed antiserum code #867, which was raised against a synthetic peptide corresponding to the C-terminus of human GIP.”
MethodSelf-citationNauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.020 · Cited by 137 · cited 1×
“In line with our results, no incretin defect were demonstrated in the first degree relatives of patients with type 2 diabetes as compared to healthy controls with comparable insulin sensitivity (24) or in women with a history of Page 12 of 30 Diabetes Care”
ResultSelf-citationHypersecretion of Gastric Inhibitory Polypeptide Following Oral Glucose in Diabetes Mellitus
Ross, S. A., Brown, J. C., & Dupré, J. (1977) · Diabetes · doi:10.2337/diab.26.6.525 · Cited by 135 · cited 1×
“The data in subjects with diabetes on GLP-1 and GIP plasma levels are conflicting with studies reporting especially reduced, unaltered and increased GIP concentrations after OGTT (2, 30-33).”
ResultKaprio, J. (2006) · Twin Research and Human Genetics · doi:10.1375/183242706779462778 · Cited by 123
Self-citationKaprio, J. A. (2006) · Twin Research and Human Genetics · doi:10.1375/twin.9.6.772 · Cited by 114
Self-citationNeuropeptide Y and peptide YY: important regulators of energy metabolism
Nguyen, A. D., Herzog, H., & Sainsbury, A. (2011) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283422f0a · Cited by 89 · cited 1×
“Our finding that leaner and heavier cotwins of obesity-discordant MZ pairs demonstrate a similar AUC for PYY levels is in contradiction with reports of decreased PYY secretion after meal in obesity in individuals (34,35).”
ResultMeier, J. J., Gallwitz, B., Askenas, M., Vollmer, K., Deacon, C. F., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1863-7 · Cited by 87
Self-citationSchousboe, K., Visscher, P. M., Henriksen, J. E., Hopper, J. L., S�rensen, T. I. A., & Kyvik, K. O. (2003) · Diabetologia · doi:10.1007/s00125-003-1165-x · Cited by 72 · cited 1×
“Heritability estimates for HOMA index, Matsuda index, AUC insulin, and AUC glucose were generally in the same range as those reported for OGTT-derived measures of glucose tolerance and indices of insulin sensitivity and secretion in a large population–based sample of adult female and male twin pairs free of diabetes o…”
ResultLundbom, J., Hakkarainen, A., Fielding, B. A., Söderlund, S., Westerbacka, J., Taskinen, M., & Lundbom, N. M. I. (2010) · NMR in Biomedicine · doi:10.1002/nbm.1483 · Cited by 67 · cited 1×
“Weight, height, whole-body fat (dualenergy X-ray absorptiometry); abdominal, subcutaneous, and intraabdominal fat (magnetic resonance imaging); and liver fat (magnetic resonance spectroscopy) were measured as described previously (13).”
MethodSelf-citationTyynismaa, H., Raivio, T., Hakkarainen, A., Ortega-Alonso, A., Lundbom, N., Kaprio, J., Rissanen, A., Suomalainen, A., & Pietiläinen, K. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1326 · Cited by 61 · cited 1×
“1 years, identified from Finn Twin16 and Finn Twin12 cohorts (n = 5,417 families) (10,11).”
BackgroundSelf-citationAssociation Studies of BMI and Type 2 Diabetes in the Neuropeptide Y Pathway
Campbell, C. D., Lyon, H. N., Nemesh, J. C., Drake, J. A., Tuomilehto, J., Gaudet, D., Zhu, X., Cooper, R., Ardlie, K., Groop, L., et al. (2007) · Diabetes · doi:10.2337/db06-1051 · Cited by 58
Genetic variants affecting incretin sensitivity and incretin secretion
Müssig, K., Staiger, H., Machicao, F. E., Häring, H., & Fritsche, A. (2010) · Diabetologia · doi:10.1007/s00125-010-1876-8 · Cited by 49 · cited 2×
“Although several polymorphisms in the GIP receptor (GIPR) have been associated with both obesity and glycemia (3,4), genetic loci predisposing to type 2 diabetes identified so far do not directly involve GLP-1 or GIP genes (5,6).”
BackgroundGranér, M., Seppälä‐Lindroos, A., Rissanen, A., Hakkarainen, A., Lundbom, N. M. I., Kaprio, J. A., Nieminen, M. S., & Pietiläinen, K. H. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.12.023 · Cited by 46 · cited 2×
“Plasma glucose and serum insulin were measured as previously described (12).”
BackgroundMethodSelf-citationThe contribution of incretin hormones to the pathogenesis of type 2 diabetes
Meier, J. J. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.007 · Cited by 46 · cited 2×
“In healthy individuals, this incretin effect accounts for up to 70% of insulin secretion in an oral glucose tolerance test (OGTT) (1).”
BackgroundSmushkin, G., Sathananthan, M., Sathananthan, A., Dalla Man, C., Micheletto, F., Zinsmeister, A. R., Cobelli, C., & Vella, A. (2012) · Diabetes · doi:10.2337/db11-1732 · Cited by 43 · cited 1×
“(29) reported in healthy individuals that TCF7L2, WFS1, and KCNQ1 genotypes had no effect on GLP-1 concentrations after an OGTT, or on b-cell responsiveness to hyperglycemic clamp and GLP-1 infusion.”
BackgroundYeung, E. H., Zhang, C., Chen, J., Bowers, K. A., Hu, F. B., Kang, G., & Qi, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0195 · Cited by 42 · cited 1×
“Polymorphisms in the PYY gene may contribute to obesity and diabetes risk (7,8).”
BackgroundRecent progress in PYY research—An update report for 8th NPY meeting
Ashby, D. R., & Bloom, S. R. (2007) · Peptides · doi:10.1016/j.peptides.2006.10.019 · Cited by 38 · cited 1×
“Our finding that leaner and heavier co-twins of obesity-discordant MZ pairs demonstrate a similar AUC for PYY levels is in contradiction with reports of decreased PYY secretion after meal in obesity in individuals (34, 35).”
ResultEffect of Glycemia on Plasma Incretins and the Incretin Effect During Oral Glucose Tolerance Test
Salehi, M., Aulinger, B., & D’Alessio, D. A. (2012) · Diabetes · doi:10.2337/db11-1825 · Cited by 38 · cited 1×
“Previous data on healthy subjects demonstrate that the incretin response is independent of prevailing glucose concentration and that GLP-1 response is rather reproducible among individuals (23).”
BackgroundMartínez‐Hervás, S., Argente, C. R., Jodar, J. G., Priego, A., Real, J. T., Carratalá, A., Carmena, R., & Ascaso, J. F. (2010) · Metabolism · doi:10.1016/j.metabol.2010.07.024 · Cited by 28
Derks, E. M., Dolan, C. V., & Boomsma, D. I. (2007) · Twin Research and Human Genetics · doi:10.1375/twin.10.1.159 · Cited by 8 · cited 1×
“Regarding the representativeness of the twin model estimates from this selected sample, it has been shown with simulated twin data that the bias resulting from the extreme concordant and discordant design is minimal (36).”
MethodNauck, M. A., Hahn, S. A., Sauerwald, A., & Schmiegel, W. (2000) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2000-5798 · Cited by 4 · cited 1×
“Although several polymorphisms in the GIP receptor (GIPR) have been associated with both obesity and glycemia (3,4), genetic loci predisposing to type 2 diabetes identified so far do not directly involve GLP-1 or GIP genes (5,6).”
Background
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“com meta-analysis of 22 clinical studies revealed no difference in glucosestimulated GLP-1 secretion between patients with type-2 diabetes and non-diabetic controls [263,264].”
BackgroundSelf-citationIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
“Regarding the secretion of GLP-1 in obesity, reduced increments in meal-related GLP-1 responses have been described with increasing body mass index, in particular in the presence of hepatic steatosis.(125) The incretin effect has been reported to be decreased in obesity,(123) even in the absence of impaired glucose to…”
BackgroundFærch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
“Radioimmunological determinations of total plasma GLP-1 concentration [intact GLP-1 plus the metabolite GLP-1(9-36)amide] were performed as described previously (23–25).”
BackgroundMethodResultSelf-citationGlucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Self-citationMetabolically healthy and unhealthy obese – the 2013 Stock Conference report
Samocha‐Bonet, D., Dixit, V. D., Kahn, C. R., Leibel, R. L., Lin, X., Nieuwdorp, M., Pietiläinen, K. H., Rabasa‐Lhoret, R., Roden, M., Scherer, P. E., et al. (2014) · Obesity Reviews · doi:10.1111/obr.12199 · Cited by 169
Self-citation
Metadata
- Authors
- Matikainen, N., Bogl, L. H., Hakkarainen, A., Lundbom, J., Lundbom, N., Kaprio, J., Rissanen, A., Holst, J. J., & Pietiläinen, K. H.
- Affiliations
- University of Helsinki (FI)
- University of Copenhagen (DK)
- Corresponding author
- Pietiläinen, Kirsi H.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-12-11
- Volume
- 37
- Issue
- 1
- Pages
- 242-251
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2141742385
- Cited by
- 63
- References
- 38
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 2 · 2020: 3 · 2019: 8 · 2018: 7 · 2017: 7 · 2016: 3 · 2015: 4 · 2014: 4 · 2013: 2
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Funders
- Novo Nordisk Fonden (#NNF10OC1013354)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- glucagon-like peptide-1, incretin response, heritability, hepatic lipid accumulation, insulin resistance, glucose-dependent insulinotropic polypeptide, peptide YY, monozygotic twins, dizygotic twins, discordant twins, oral glucose tolerance test, type 2 diabetes risk
- MeSH terms
- Adult, Blood Glucose, Body Weight, Female, Gastric Inhibitory Polypeptide, Glucose Tolerance Test, Humans, Insulin, Insulin Resistance, Liver, Male, Obesity, Peptide Fragments, Lipid Metabolism, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.